Sofpironium bromide is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). It reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site and also has a high affinity for the M1, M2, M4, and M5 subtypes. Sofpironium bromide is metabolized mainly through non-enzymatic hydrolysis, and also through oxidative metabolism via CYP2D6 and CYP3A4. In a rat model, it reduces footpad sweating induced by Pilocarpine (a muscarinic receptor agonist). It exhibits anticholinergic activity by inhibiting the contractile activity of guinea pig ileal tissue in a concentration-dependent manner.
- Reduces sweating by inhibiting M3 muscarinic receptors
- High affinity for M1, M2, M4, and M5 muscarinic receptor subtypes
- Metabolized mainly through non-enzymatic hydrolysis
- Exhibits anticholinergic activity